Traws Pharma Files 8-K

TL;DR

Traws Pharma (fka Onconova) filed an 8-K on 12/17/25. Standard reporting.

AI Summary

Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on December 17, 2025, reporting other events and financial statements. The company, incorporated in Delaware, operates in the pharmaceutical preparations sector and is located in Newtown, PA.

Why It Matters

This filing indicates Traws Pharma is making a formal report to the SEC regarding its operations and financial status, which is crucial for investors to stay informed about the company's activities.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for reporting purposes and does not contain specific news that would inherently increase risk.

Key Players & Entities

• Traws Pharma, Inc. (company) — Registrant
• Onconova Therapeutics, Inc. (company) — Former company name
• December 17, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 12 Penns Trail Newtown, PA 18940 (address) — Business address

FAQ

Filing Documents

• tm2533729d1_8k.htm (8-K) — 27KB
• tm2533729d1_ex99-1.htm (EX-99.1) — 26KB
• tm2533729d1_ex99-1img001.jpg (GRAPHIC) — 13KB
• 0001104659-25-121749.txt ( ) — 238KB
• tmb-20251217.xsd (EX-101.SCH) — 3KB
• tmb-20251217_lab.xml (EX-101.LAB) — 33KB
• tmb-20251217_pre.xml (EX-101.PRE) — 22KB
• tm2533729d1_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On December 17, 2025, Traws Pharma, Inc. (the "Company") issued a press release (the "Press Release") announcing positive interim data for its Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated by reference into this Item 8.01. Forward-Looking This Current Report, including Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes," "will" and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements

Forward-looking statements in this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company's business and the accuracy of the forward-looking statements contained herein.

01 Financial

Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 17, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR